NP39724 Generic and Biosimilar Cancer Medicines

Award

Buyers

Value

£10,396,962

Suppliers

Classifications

  • Pharmaceutical products

Tags

  • award
  • contract

Published

1 month ago

Description

Supply of Generic and Biosimilar Cancer Medicines to NHS Scotland.

Documents

Premium

Bypass the hassle of outdated portals. Get all the information you need right here, right now.

  • Contract Agreement

    The official contract terms, conditions, and scopes of work.

    Download

  • Award Notice

    Details on the tender award and selected suppliers.

    Download

Similar Contracts

Open

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: [email protected]

NHS England

NHS England

Published 1 month ago
Open

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/><br/>CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines – Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/><br/>CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines – Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

NHS England

NHS England

Published 1 month ago
Open

IMP Manufacture, Labelling and Packaging DPS

The London School of Hygiene and Tropical Medicine (LSHTM) is implementing a Dynamic Purchasing System (DPS) for the procurement of services related to the provision of investigational medicinal products (IMPs) for clinical trials. The DPS is intended to be a long term, 10 year, system to support the work of the CTU for both large and small trials.

London School of Hygiene & Tropical Medicine

London School of Hygiene & Tropical Medicine

Published 7 months ago

AI Bid Assistant

Our AI-powered tool to help you create winning bids is coming soon!

View Contract Source Save Contract

Organisation

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Body governed by public law

[email protected]

+44 1312756000

+44 7919830195

+44 7471112086

Timeline complete

Publish
Bid
Evaluate
Award
Complete